Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
-6.49% $6.63
America/New_York / 28 mar 2024 @ 16:00
FUNDAMENTALS | |
---|---|
MarketCap: | 32.39 mill |
EPS: | -2.85 |
P/E: | -2.33 |
Earnings Date: | May 05, 2024 |
SharesOutstanding: | 4.89 mill |
Avg Daily Volume: | 0.0397 mill |
RATING 2024-03-28 |
---|
B- |
Sell |
RATINGS | ||
---|---|---|
Rating CashFlow: | Neutral | |
Return On Equity: | Sell | |
Return On Asset: | Sell | |
DE: | Sell | |
P/E: | Sell | |
Price To Book: | Neutral |
QUARTER GROWTHS | ||||||
---|---|---|---|---|---|---|
2/22 | 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | |
Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
Gr.Profit | n/a | n/a | n/a | n/a | n/a | |
Ebit | ||||||
Asset | ||||||
Debt | n/a | n/a |
PE RATIO: COMPANY / SECTOR |
---|
0.00x |
Company: PE -2.33 | sector: PE -3.05 |
PE RATIO: COMPANY / INDUSTRY |
---|
-0.40x |
Company: PE -2.33 | industry: PE 5.88 |
DISCOUNTED CASH FLOW VALUE |
---|
$1.137 (-82.85%) $-5.49 |
Date: 2024-03-29 |
Expected Trading Range (DAY) |
---|
$ 6.23 - 7.03 ( +/- 6.05%) |
ATR Model: 14 days |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-03-05 | Windsor James Brian | Buy | 2 000 | Common Stock |
2024-03-05 | Windsor James Brian | Sell | 2 | Series X Non-Voting Convertible Preferred |
2024-02-28 | Ambros Reinhard J. | Buy | 2 725 | Stock Option (right to buy) |
2024-02-28 | Von Rickenbach Josef H | Buy | 2 725 | Stock Option (right to buy) |
2023-12-15 | Windsor James Brian | Buy | 225 | Common Stock |
INSIDER POWER |
---|
-28.78 |
Last 94 transactions |
Buy: 25 085 053 | Sell: 1 207 893 |
Indicator Signals | |
---|---|
RSI 21 | |
SMA | |
Trend | |
Trend 2 | |
Trend 3 | |
MACD |
Volume Signals | |
---|---|
Price | $6.63 (-6.49% ) |
Volume | 0.0227 mill |
Avg. Vol. | 0.0397 mill |
% of Avg. Vol | 57.17 % |
Signal 1: | |
Signal 2: |
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
Date | Signal | @ | Closed | % |
---|
Aileron Therapeutics, Inc. operates as a clinical stage chemoprotection oncology company in the United States. The company is developing ALRN-6924, which is in Phase 1 trial for solid tumor and lymphoma; Phase 2a clinical trial to treat peripheral T-cell lymphoma; Phase I clinical trial for the treatment of acute myeloid leukemia (AML) and advanced myelodysplastic syndrome (MDS); Phase 1b trial to test the combination of ALRN-6924 and cytarabine, or Ara-C, in patients with MDS; and a Phase 2a combination trial of ALRN-6924 and palbociclib in patients with tumors harboring MDM2 amplifications co-amplifications, as well as for patients with p53-mutated small cell lung cancer that has completed Phase 1b clinical trial. It has a license agreement with Dana-Farber Cancer Institute and Harvard College; and Umicore Precious Metals Chemistry USA, LLC. The company was formerly known as Renegade Therapeutics, Inc. and changed its name to Aileron Therapeutics, Inc. in February 2007. Aileron Therapeutics, Inc. was incorporated in 2001 and is based in Boston, Massachusetts.